Harrington RA
Division of Cardiology, Duke University Medical Center, Durham, NC and Duke Databank for Cardiovascular Disease, Erwin Square, Bay A, 2024 West Main Street, Durham, NC 27705.
J Thromb Thrombolysis. 1995;2(1):21-28. doi: 10.1007/BF01063157.
Ischemic complications of percutaneous coronary intervention occur commonly and are among the major limitations of the procedure. Both platelets and thrombin play an essential role in the response to the arterial injury that follows coronary intervention and in the pathophysiology of the ischemic complications of the procedure. Aspirin and heparin are essential treatments for the patient undergoing coronary intervention. Novel thrombin and platelet inhibitors are being developed that may be useful for improving both acute and long-term clinical outcomes of percutaneous coronary intervention.
经皮冠状动脉介入治疗的缺血性并发症很常见，是该手术的主要局限性之一。血小板和凝血酶在冠状动脉介入治疗后对动脉损伤的反应以及该手术缺血性并发症的病理生理过程中都起着至关重要的作用。阿司匹林和肝素是接受冠状动脉介入治疗患者的重要治疗药物。新型凝血酶和血小板抑制剂正在研发中，可能有助于改善经皮冠状动脉介入治疗的急性和长期临床疗效。
